About Novavax
Novavax is a company based in Gaithersburg (United States) founded in 1987. The company has 952 employees as of December 31, 2024. Novavax has completed 2 acquisitions, including Isconova and PRAHA VACCINES. Novavax offers products and services including Matrix-M Adjuvant and Recombinant Nanoparticle Vaccine Technology. Novavax operates in a competitive market with competitors including Adaptive Biotechnologies, Moderna, Generate Biomedicines, HOOKIPA Pharma and Brii Biosciences, among others.
- Headquarter Gaithersburg, United States
- Employees 952 as on 31 Dec, 2024
- Stage Public
-
Sectors
HealthcareTechnology
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Novavax, Inc.
-
Annual Revenue
$682.16 M (USD)-30.65as on Dec 31, 2024
-
Net Profit
-$187.5 M (USD)65.6as on Dec 31, 2024
-
EBITDA
-$183.47 M (USD)50.92as on Dec 31, 2024
-
Latest Funding Round
$84.5 M (USD), Post-IPO
Sep 08, 2023
-
Investors
NIH
& 11 more
-
Employee Count
952
as on Dec 31, 2024
-
Investments & Acquisitions
Isconova
& 1 more
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
IPO & Listings of Novavax
Novavax is a publicly listed company on the NASDAQ with ticker symbol NVAX in USA, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
Products & Services of Novavax
Novavax offers a comprehensive portfolio of products and services, including Matrix-M Adjuvant and Recombinant Nanoparticle Vaccine Technology.
Enhances immune response in vaccines for infectious diseases
Develops protein-based vaccines for global health protection
People of Novavax
Unlock access to complete
Unlock access to complete
Leadership Team
93 people
Software Development Team
55 people
Senior Team
22 people
Operations Team
22 people
Product Management Team
17 people
Finance and Accounting
16 people
Legal and Compliance
11 people
Scientist Team
7 people
Unlock access to complete
Funding Insights of Novavax
Investors in Novavax
Novavax has secured backing from 12 investors, including institutional and venture fund investors. Prominent investors backing the company include NIH, Gates Foundation and HHS.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Healthcare investments are targeted by this private equity firm.
|
Locked | Locked | Locked | |
|
-
|
Locked | Locked | Locked | |
|
Innovative vaccines are developed and manufactured by SK bioscience.
|
Locked | Locked | Locked |
Investor details for Novavax
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Novavax
Novavax has strategically engaged in corporate development activities, having acquired 2 companies. Notable acquisitions include Isconova and PRAHA VACCINES.
Investment portfolio details for Novavax
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Serums and vaccines are developed and produced by PRAHA VACCINES.
|
Locked | Locked | 2017 | Locked | |
|
Vaccine adjuvants are developed for infectious diseases and veterinary applications.
|
Locked | Locked | 1999 | Locked |
Complete acquisition details for Novavax
Transaction dates, acquired stakes, disclosed values, domains, and locations require an active premium plan.
- Transaction dates
- Acquired stakes
- Disclosed values
- Domains and locations
Verified entity values are shown only after access is granted.
Financial Statements - Novavax
Detailed financials for Novavax
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Novavax Comparisons
Peer comparison for Novavax
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Novavax
Novavax operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Adaptive Biotechnologies, Moderna, Generate Biomedicines, HOOKIPA Pharma and Brii Biosciences, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Clinical diagnostics and drug discovery for immune diseases are provided.
|
|
| Locked | Locked | Locked |
mRNA-based therapeutics for diseases including cancer and infections are developed.
|
|
| Locked | Locked | Locked |
Developer of novel protein-based therapeutics using machine learning and biological engineering
|
|
| Locked | Locked | Locked |
Developer of immunotherapies for the treatment of infectious diseases and cancer
|
|
| Locked | Locked | Locked |
Developer of biologics to treat hepatitis B infection
|
|
| Locked | Locked | Locked |
VBI Vaccines is engaged in developing vaccines and immunotherapeutics.
|
Detailed competitors of Novavax
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Novavax
Complete news archive for Novavax
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Novavax
Novavax was founded in 1987 and raised its 1st funding round 18 years after it was founded.
Novavax is headquartered in Gaithersburg, United States. It is registered at Gaithersburg, Maryland, United States.
John Jacobs is the current CEO of Novavax.
As of Dec 31, 2024, the latest employee count at Novavax is 952.
Annual revenue of Novavax is $682.16M as on Dec 31, 2024.
Novavax was founded in 1987 and is headquartered in Gaithersburg, United States. Vaccines are developed by the company in the biotechnology sector, focusing on recombinant nanoparticle platforms and adjuvant technology. The pipeline encompasses candidates for respiratory syncytial virus, coronavirus, malaria, Ebola, and seasonal quadrivalent influenza. Operations center on advancing these vaccine technologies for global health needs.
Novavax's top competitors include Moderna, Adaptive Biotechnologies and Generate Biomedicines.
Novavax offers Matrix-M Adjuvant and Recombinant Nanoparticle Vaccine Technology.
Yes, Novavax is publicly traded on NASDAQ under the ticker symbol NVAX.
Novavax has made 2 acquisitions, including Isconova, and PRAHA VACCINES.
Novavax has 12 investors. Key investors include NIH, Gates Foundation, HHS, Path, and RA Capital.
The ticker symbol of Novavax is NVAX on NASDAQ.